TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15042114

Group type: EXPERIMENTAL
Intervention: Eprosartan monotherapy (600-1200 mg/day)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Eprosartan monotherapy
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Eprosartan + HCTZ (12.5 mg)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Eprosartan + HCTZ
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 11504275

Group type: EXPERIMENTAL
Intervention: AP1903 0.01 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AP1903 0.05 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AP1903 0.1 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AP1903 0.5 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: AP1903 1.0 mg/kg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 28
Study: 9360205

Group type: EXPERIMENTAL
Intervention: Oral rehydration followed by Lactobacillus casei strain GG
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral rehydration
Number of subjects: 100
Study: 8285751

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG 10(8) colony forming units twice a day for two weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 20
Study: 3556374

Group type: EXPERIMENTAL
Intervention: buprenorphine 7.5 micrograms/kg i.v.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: fentanyl 2.5 micrograms/kg i.v.
Number of subjects: 7

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study: 31778277

Group type: EXPERIMENTAL
Intervention: Intensive intervention (lifestyle intervention plus supervised exercise 3 sessions/week)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control intervention (family-based lifestyle and psycho-educational program)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intensive intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 102
Study: 31058615

Group type: EXPERIMENTAL
Intervention: Bleaching + 10% green tea
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bleaching + 5% proanthocyanidins
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bleaching + 10% alpha-tocopherol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bleaching + 10% sodium ascorbate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Negative control - no bleaching treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Positive control - bleaching
Number of subjects: 120
Study: 29098841

Group type: EXPERIMENTAL
Intervention: Sanbitang recipe (TCM group)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Methotrexate tablets (chemical medicine group)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Sanbitang recipe and methotrexate tablets (TCM combined with chemical medicine group)
Number of subjects: 168
Study: 25929919

Group type: EXPERIMENTAL
Intervention: Oral etoposide (60 mg/m²/d on days 1‐10, followed by 11 days of rest)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 75
Study: 23073721

Group type: EXPERIMENTAL
Intervention: Verbalization of motor experience
Number of subjects: 80

Group type: COMPARATOR
Intervention: Irrelevant verbal task
Number of subjects: 80
Study: 21557207

Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate (SSH) administered intravenously for 7 days
Number of subjects: 31
Study: 19943787

Group type: EXPERIMENTAL
Intervention: Vaccination schedule
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 17034904

Group type: EXPERIMENTAL
Intervention: Teaching strategy including calculation assignments and medication calculation classes
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (previous sophomore class)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 54
Study: 15346657

Group type: EXPERIMENTAL
Intervention: Methimazole treatment
Number of subjects: 49
Study: 10708052

Group type: EXPERIMENTAL
Intervention: Triple therapy (zidovudine + lamivudine + ritonavir)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Double therapy (zidovudine + lamivudine)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 42
Study: 9100591

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8403956

Group type: EXPERIMENTAL
Intervention: Continuous nebulization of albuterol (0.3 mg/kg/hr)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intermittent nebulization of albuterol (0.3 mg/kg over 20 mins every hour)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Continuous nebulization of albuterol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intermittent nebulization of albuterol
Number of subjects: 17
Study: 3511936

Group type: EXPERIMENTAL
Intervention: Once daily theophylline
Number of subjects: 15
Study: 3358886

Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30231787

Group type: EXPERIMENTAL
Intervention: Chewing sugar-free gum 2 hours after recovery for at least half an hour and at 2-hour intervals during daytime
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Oral fluids 6 hours postoperatively
Number of subjects: 372

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 372
Study: 30937940

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg oral dose
Number of subjects: 0
Study: 28375647

Group type: EXPERIMENTAL
Intervention: Once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 μg/62.5 μg/25 μg; ELLIPTA inhaler)
Number of subjects: 1810

Group type: COMPARATOR
Intervention: Twice-daily ICS/LABA therapy (budesonide/formoterol 400 μg/12 μg; Turbuhaler)
Number of subjects: 1810

Group type: EXPERIMENTAL
Intervention: Once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol)
Number of subjects: 1810

Group type: COMPARATOR
Intervention: Twice-daily ICS/LABA therapy (budesonide/formoterol)
Number of subjects: 1810
Study: 25816336

Group type: EXPERIMENTAL
Intervention: Emotional abuse from a current partner
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Emotional abuse at baseline or prior to the first HIV+ test
Number of subjects: 103
Study: 23265918

Group type: EXPERIMENTAL
Intervention: eSMART-MH (avatar-based depression self-management intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 0
Study: 21537720

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Haloperidol plus promethazine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Haloperidol plus midazolam
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Haloperidol alone
Number of subjects: 150
Study: 19590476

Group type: EXPERIMENTAL
Intervention: G-ER 1800 mg once-daily administered in the evening
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: G-ER 1800 mg asymmetric divided dose (600 mg AM and 1200 mg PM)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo G-ER
Number of subjects: 158
Study: 17044733

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg/day for 6 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12929470

Group type: EXPERIMENTAL
Intervention: Per2/Ind0.625
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Perindopril 2 mg
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Indapamide 0.625 mg
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study: 11071065

Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment for 16 weeks
Number of subjects: 197

Group type: COMPARATOR
Intervention: Xbal polymorphism
Number of subjects: 197

Group type: COMPARATOR
Intervention: Ins/del and EcoRI polymorphisms
Number of subjects: 197
Study: 9052620

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) group: five subconjunctival injections of 5 mg 5‐FU, starting from day 8 after surgery, one injection per week.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group: no injections.
Number of subjects: 24
Study: 8448099

Group type: EXPERIMENTAL
Intervention: 18-gauge Tuohy-Schliff needle/20-gauge catheter combination (group 1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 20-gauge Quincke point needle/24-gauge catheter combination (group 2)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 22-gauge Quincke point needle (control group)
Number of subjects: 200
Study: 3512898

Group type: EXPERIMENTAL
Intervention: Autogenic training (group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Relaxation therapy with biological feedback (BFB) (group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No psychological influences (group 3, control)
Number of subjects: 80
Study: 30940872

Group type: EXPERIMENTAL
Intervention: CBCT protocol with 70 kVp, 16 mAs, and 180 µm voxel size
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultra-low dose protocols with 400 µm voxel size and 7.4 mAs
Number of subjects: 0
Study: 27392611

Group type: EXPERIMENTAL
Intervention: Fluroshield
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Helioseal Clear Chroma
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Single Bond + F
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Excite + H
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Overall sealant prevention
Number of subjects: 65
Study: 25739317

Group type: EXPERIMENTAL
Intervention: Supine voluntary deep-inspiratory breath-hold (VBH) technique
Number of subjects: 34

Group type: COMPARATOR
Intervention: Free-breathing prone technique
Number of subjects: 34
Study: 23930843

Group type: EXPERIMENTAL
Intervention: HFM-AB1 (500 ml antioxidant beverage 1; apple, grape, blueberry and pomegranate juices and grape skin, grape seed and green tea extracts)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: HFM-AB2 (500 ml antioxidant beverage 2; pineapple, black currant and plum juices)
Number of subjects: 14

Group type: COMPARATOR
Intervention: HFM-PB (500 ml placebo beverage, free from fruit)
Number of subjects: 14
Study: 22433978

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 19581564

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: High-dose right unilateral ECT
Number of subjects: 319

Group type: COMPARATOR
Intervention: Moderate-dosage bilateral ECT
Number of subjects: 319
Study: 17353079

Group type: EXPERIMENTAL
Intervention: Siemens pulse oximeter (group S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Philips pulse oximeter (group P)
Number of subjects: 0
Study: 15037554

Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase inhibitor (L-NMMA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Phenylephrine (vasoconstrictor control)
Number of subjects: 18
Study: 12147149

Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide 500 mg/2.5 mg
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Metformin-glibenclamide 500 mg/5 mg
Number of subjects: 411

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 411

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 411
Study: 10372585

Group type: EXPERIMENTAL
Intervention: 30-year health profiles, 27 empirical tests of independence
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 30-year health profiles, 15 additional tests designed to be more sensitive to independence violations
Number of subjects: 98
Study: 8848192

Group type: EXPERIMENTAL
Intervention: Selective anesthesia of the right hemisphere during right intracarotid barbiturate infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 20
Study: 2362257

Group type: COMPARATOR
Intervention: 4-6 cups filtered coffee per day
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 4-6 cups boiled coffee per day
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: No coffee at all
Number of subjects: 107
Study: 373992

Group type: EXPERIMENTAL
Intervention: 5% bufexamac cream
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.1% betamethasone valerate cream
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 72
Study: 31174974

Group type: EXPERIMENTAL
Intervention: Arterial lactate level > 3.2 mmol/L and clearance of <20%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Venous lactate concentrations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Arterial lactate concentrations
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lactate clearance
Number of subjects: 100
Study: 30401602

Group type: EXPERIMENTAL
Intervention: Preoperative oral carbohydrate solution (OCS) administration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no food or drink before surgery)
Number of subjects: 100
Study: 29017451

Group type: EXPERIMENTAL
Intervention: FilmArray® POC testing (intervention)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Routine, laboratory-based RP PCR testing (control)
Number of subjects: 545
Study: 25494658

Group type: EXPERIMENTAL
Intervention: Essential oil (EO) mouthrinse (40 mL/day for 90 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo mouthrinse (40 mL/day for 90 days)
Number of subjects: 120
Study: 24070431

Group type: EXPERIMENTAL
Intervention: DPV 0.05% gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Matched placebo gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Universal placebo gel
Number of subjects: 48
Study: 21933896

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 35) managed by a diabetes centre with specialized management via a primary health-care nurse using a PDA-type blood glucometer
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 35)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 19336551

Group type: EXPERIMENTAL
Intervention: BRCAPRO model
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: BOADICEA model
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Both models
Number of subjects: 3
Study: 17691076

Group type: EXPERIMENTAL
Intervention: Amisulpride (200-800 mg/d)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Olanzapine (5-20 mg/d)
Number of subjects: 377
Study: 15015012

Group type: EXPERIMENTAL
Intervention: Alzheimer's disease patients
Number of subjects: 51
Study: 11174228

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (50 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prochlorperazine alone (Control)
Number of subjects: 100
Study: 9744776

Group type: EXPERIMENTAL
Intervention: Standard-dose carboplatin (Calvert formula based on 24-h Ccr)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Standard-dose carboplatin (CG-Calvert formula)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Standard-dose carboplatin (Chatelut formula)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-dose carboplatin (Calvert formula based on 24-h Ccr)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-dose carboplatin (CG-Calvert formula)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Low-dose carboplatin (Chatelut formula)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Standard-dose carboplatin (AUCs aiming for target AUCs of 5 and 6 mg x min/ml)
Number of subjects: 52
Study: 7794302

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/d
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 2929556

Group type: EXPERIMENTAL
Intervention: Clonidine 0.3 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31538430

Group type: EXPERIMENTAL
Intervention: Short-term exposure to PM10 exceeding 100 µg/m3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very short-term exposure to PM10 exceeding 100 µg/m3 for 2 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term exposure to PM2.5 exceeding 50 µg/m3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very short-term exposure to PM2.5 exceeding 50 µg/m3 for 2 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PM10 exposure on the 24-hr event day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PM2.5 exposure
Number of subjects: 0
Study: 28558817

Group type: EXPERIMENTAL
Intervention: Aerobic exercise, strength training, and physical therapy (3 months, biweekly 90-min sessions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Aerobic exercise, strength training, and physical therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 25945691

Group type: EXPERIMENTAL
Intervention: Corticosteroid group (CG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 100
Study: 21996417

Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe combination
Number of subjects: 1563

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1563
Study: 22086108

Group type: EXPERIMENTAL
Intervention: Intravaginal micronized natural progesterone (200 mg daily)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group receiving only tocolysis
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study: 19926893

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 16376845

Group type: EXPERIMENTAL
Intervention: Excision-suture
Number of subjects: 125

Group type: COMPARATOR
Intervention: Resection-anastomosis
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study: 15103431

Group type: EXPERIMENTAL
Intervention: Rotating stimulation of real acupoints (Liv3 and G40)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-rotating stimulation of real acupoints (Liv3 and G40)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Stimulation of sham point (non-rotating and rotating)
Number of subjects: 15
Study: 10930686

Group type: EXPERIMENTAL
Intervention: Combination of Russian live attenuated and US inactivated trivalent influenza vaccines
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Live vaccine alone
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Inactivated vaccine alone
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Live vaccine (alone or in combination with inactivated vaccine)
Number of subjects: 614

Group type: EXPERIMENTAL
Intervention: Combination vaccines
Number of subjects: 614
Study: 9031444

Group type: EXPERIMENTAL
Intervention: Dalteparin (Fragmin) 5000 i.u. once daily for 4 weeks
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 8081065

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3 supplements (1.2 g calcium and 800 IU vitamin D3 daily)
Number of subjects: 3270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3270
Study: 2577253

Group type: EXPERIMENTAL
Intervention: Sufentanil 80 micrograms
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sufentanil 50 micrograms
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 45
Study: 319956

Group type: EXPERIMENTAL
Intervention: 2% miconazole nitrate lotion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% miconazole nitrate lotion (for therapeutic failures)
Number of subjects: 30
Study: 31222319

Group type: COMPARATOR
Intervention: Alg (1% microalgae, no additional choline chloride)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ch0.1 (Alg plus choline chloride at 0.1%)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Ch0.2 (Alg plus choline chloride at 0.2%)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (0% microalgae)
Number of subjects: 56
Study: 28553726

Group type: EXPERIMENTAL
Intervention: Educational module for Latino parents about the health effects of sweet beverages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control module
Number of subjects: 0
Study: 26765317

Group type: EXPERIMENTAL
Intervention: Androgen deprivation treatment (ADT)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Poor Eastern Cooperative Oncology Group performance status (PS)
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: High analgesic consumption
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: Low hemoglobin
Number of subjects: 915

Group type: EXPERIMENTAL
Intervention: High Soloway score (extent of disease observed on the scan)
Number of subjects: 915

Group type: COMPARATOR
Intervention: Age, treatment, cardiovascular comorbidity, T category, grade of malignancy, serum estrogen level, and SHBG at enrolment
Number of subjects: 915
Study: 23740357

Group type: EXPERIMENTAL
Intervention: Multiplanar reconstruction computed tomography (CT)
Number of subjects: 44
Study: 21906903

Group type: EXPERIMENTAL
Intervention: Covered balloon-expandable stent
Number of subjects: 125

Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 125
Study: 19553072

Group type: EXPERIMENTAL
Intervention: Rotating-platform (RP) prosthesis
Number of subjects: 140

Group type: COMPARATOR
Intervention: Fixed-bearing (FB) prosthesis
Number of subjects: 140

Group type: COMPARATOR
Intervention: Both FB and RP prostheses
Number of subjects: 140
Study: 17116004

Group type: EXPERIMENTAL
Intervention: Double‐blind treatment with metoprolol
Number of subjects: 809

Group type: EXPERIMENTAL
Intervention: Double‐blind treatment with verapamil
Number of subjects: 809
Study: 15574098

Group type: EXPERIMENTAL
Intervention: Passive Static Stretch (PSS)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Active Static Stretch (ASST)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Active Dynamic Stretch (ADS)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Static Dynamic Stretch (SDS)
Number of subjects: 97